Stanford researchers have developed a novel technology using extracellular vesicles (EVs) to selectively suppress immune responses to AAV vectors, enabling safer and more effective gene therapy.
Stanford researchers have developed a novel gene therapy vector, AAV-capGL to overcome immune barriers that currently limit the efficacy and safety of adeno-associated virus (AAV)-based gene therapies.